Tyrosine phosphorylation of p145met mediated by EGFR and Src is required for serum-independent survival of human bladder carcinoma cells

Journal of Cell Science

Volumn 119, Issue 22, 2006, Pages 4623-4633

  Yamamoto, Natsumi ^a   Mammadova, Gunay ^a   Song, Robert X D ^b   Fukami, Yasuo ^a   Sato, Ken Ichi ^a  

^a KOBE UNIVERSITY   (Japan)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Cancer cells; EGFR; Met; Serum independent growth; Signal transduction; Src

Indexed keywords

2,3 DIHYDRO 2 OXO 3 (4,5,6,7 TETRAHYDRO 1H INDOL 2 YLMETHYLENE) 1H INDOLE 5 SULFONIC ACID DIMETHYLAMIDE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; CASPASE; CELL PROTEIN; COPPER ION; EPIDERMAL GROWTH FACTOR RECEPTOR; LIGAND; MONOCLONAL ANTIBODY; PROTEIN P145; PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR; CARBAZOLE DERIVATIVE; HGF PROTEIN, HUMAN; INDOLE DERIVATIVE; K 252; PROTEIN SUBUNIT; SCATTER FACTOR; SULFONAMIDE; TYROSINE; TYRPHOSTIN; TYRPHOSTIN A46;

ARTICLE; AUTOCRINE EFFECT; BLADDER CARCINOMA; CANCER CELL CULTURE; CANCER GROWTH; CARCINOMA CELL; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; CULTURE MEDIUM; DOWN REGULATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; AMINO ACID SEQUENCE; APOPTOSIS; BLADDER TUMOR; DRUG ANTAGONISM; METABOLISM; MOLECULAR GENETICS; PHOSPHORYLATION; PHYSIOLOGY; TUMOR CELL LINE;

AMINO ACID SEQUENCE; APOPTOSIS; CARBAZOLES; CELL LINE, TUMOR; CELL SURVIVAL; CULTURE MEDIA, SERUM-FREE; ENZYME ACTIVATION; HEPATOCYTE GROWTH FACTOR; HUMANS; INDOLES; MOLECULAR SEQUENCE DATA; PHOSPHORYLATION; PROTEIN SUBUNITS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; SULFONAMIDES; TYROSINE; TYRPHOSTINS; URINARY BLADDER NEOPLASMS;

EID: 33845713565     PISSN: 00219533     EISSN: None     Source Type: Journal    
DOI: 10.1242/jcs.03236     Document Type: Article

References (68)

1. Abella, J. V., Peschard, P., Naujokas, M. A., Lin, T., Saucier, C., Urbe, S. and Park, M. (2005). Met/Hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation. Mol. Cell. Biol. 25, 9632-9645.
2. Biscardi, J. S., Ishizawar, R. C., Silva, C. M. and Parsons, S.J. (2000). Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer. Breast Cancer Res. 2, 203-210.
3. Bolanos-Garcia, V. M. (2005). MET meet adaptors: functional and structural implications in downstream signalling mediated by the Met receptor. Mol. Cell. Biochem. 276, 149-157.
4. Bromann, P. A., Korkaya, H. and Courtneidge, S. A. (2004). The interplay between Src family kinases and receptor tyrosine kinases. Oncogene 23, 7957-7968.
5. Brown, M. T. and Cooper, J. A. (1996). Regulation, substrates and functions of src. Biochim. Biophys. Acta 1287, 121-149.
6. Carpenter, G. (1987). Receptors for epidermal growth factor and other polypeptide mitogens. Annu. Rev. Biochem. 56, 881-914.
7. Chan, P. C., Chen, Y. L., Cheng, C. H., Yu, K. C., Cary, L. A., Sim, K. H., Ho, W. L. and Chen, H. C. (2003). Src phosphorylates Grb2-associated binder 1 upon hepatocyte growth factor stimulation. J. Biol. Chem. 278, 44075-44082.
8. Cross, M. and Dexter, T. M. (1991). Growth factors in development, transformation, and tumorigenesis. Cell 64, 271-280.
9. Cursi, S., Rufini, A., Stagni, V., Condo, I., Matafora, V., Bachi, A., Bonifazi, A. P., Coppola, L., Superti-Furga, G., Testi, R. et al. (2006). Src kinase phosphorylates caspase-8 on Tyr380: a novel mechanism of apoptosis suppression. EMBO J. 25, 1895-1905.
10. Cutrupi, S., Baldanzi, G., Gramaglia, D., Maffe, A., Schaap, D., Giraudo, E., van Blitterswijk, W., Bussolino, F., Comoglio, P. M. and Graziani, A. (2000). Src-mediated activation of alpha-diacylglycerol kinase is required for hepatocyte growth factor-induced cell motility. EMBO J. 19, 4614-4622.
11. Deuel, T. F. (1987). Polypeptide growth factors: roles in normal and abnormal cell growth. Annu. Rev. Cell Biol. 3, 443-492.
12. Epstein, R. J., Druker, B. J., Roberts, T. M. and Stiles, C. D. (1990). Modulation of a Mr 175,000 c-neu receptor isoform in G8/DHFR cells by serum starvation. J. Biol. Chem. 265, 10746-10751.
13. Fischer, O. M., Hart, S., Gschwind, A. and Ullrich, A. (2003). EGFR signal transactivation in cancer cells. Biochem. Soc. Trans. 31, 1203-1208.
14. Frame, M. C. (2002). Src in cancer: deregulation and consequences for cell behaviour. Biochim. Biophys. Acta 1602, 114-130.
15. Fukami, Y, Tokmakov, A. A., Konaka, K. and Sato, K. (1999). Peptide inhibitors of the mitogen-activated protein kinase pathway: a structure-mimetic peptide corresponding to the conserved inter-DFG-APE region in the kinase domain. Pharmacol. Ther. 82, 399-407.
16. Griffiths, G. J., Koh, M. Y., Brunton, V. G., Cawthorne, C., Reeves, N. A., Greaves, M., Tilby, M. J., Pearson, D. G, Ottley, C. J., Workman, P. et al. (2004). Expression of kinase-defective mutants of c-Src in human metastatic colon cancer cells decreases Bcl-xL and increases oxaliplatin- and Fas-induced apoptosis. J. Biol. Chem. 279. 46113-46121.
17. Guerrero, J., Santibanez, J. F., Gonzalez, A. and Martinez, J. (2004). EGF receptor transactivation by urokinase receptor stimulus through a mechanism involving Src and matrix metalloproteinases. Exp. Cell Res. 292, 201-208.
18. Hammond, D. E., Urbe, S., Vande Woude, G. F. and Clague, M. J. (2001). Down-regulation of MET, the receptor for hepatocyte growth factor. Oncogene 20, 2761-2770.
19. 1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells. J. Cell. Physiol. 207, 261-270.
20. Heldin, C. H. and Westermark, B. (1989). Growth factors as transforming proteins. Eur. J. Biochem. 184, 487-496.
21. Hung, W. and Elliott, B. (2001). Co-operative effect of c-Src tyrosine kinase and Stat3 in activation of hepatocyte growth factor expression in mammary carcinoma cells. J. Biol. Chem. 276, 12395-12403.
22. Irby, R. B. and Yeatman, T. J. (2000). Role of Src expression and activation in human cancer. Oncogene 19, 5636-5642.
23. Ishizawar, R. and Parsons, S. J. (2004). c-Src and cooperating partners in human cancer. Cancer Cell 6, 209-214.
24. Jeffers, M., Taylor, G. A., Weidner, K. M., Omura, S. and Vande Woude, G. F. (1997). Degradation of the Met tyrosine kinase receptor by the ubiquitin-proteasome pathway. Mol. Cell. Biol. 17, 799-808.
25. Jiang, W. G., Martin, T. A., Parr, C., Davies, G., Matsumoto, K. and Nakamura, T. (2005). Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit. Rev. Oncol. Hematol. 53, 35-69.
26. Kadono, Y., Okada, Y., Namiki, M., Seiki, M. and Sato, H. (1998). Transformation of epithelial Madin-Darby canine kidney cells with p60(v-src) induces expression of membrane-type 1 matrix metalloproteinase and invasiveness. Cancer Res. 58, 2240-2244.
27. Laemmli, U. K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685.
28. Lang, R. A. and Burgess, A. W. (1990). Autocrine growth factors and tumourigenic transformation. Immunol. Today 11, 244-249.
29. Luo, L., Yano, N. and Luo, J. Z. (2006). The molecular mechanism of EGF receptor activation in pancreatic β-cells by thyrotropin-releasing hormone. Am. J. Physiol. Endocrinol. Metab. 290, E889-E899.
30. Maa, M. C., Leu, T. H, McCarley, D. J., Schatzman, R. C. and Parsons, S. J. (1995). Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: implications for the etiology of multiple human cancers. Proc. Natl. Acad. Sci. USA 92, 6981-6985.
31. Maejima, Y., Ueba, H., Kuroki, M., Yasu, T., Hashimoto, S., Nabata, A, Kobayashi, N., Ikeda, N., Saito, M. and Kawakami, M. (2003). Src family kinases and nitric oxide production are required for hepatocyte growth factor-stimulated endothelial cell growth. Atherosclerosis 167, 89-95.
32. Mellon, K., Wright, C., Kelly, P., Horne, C. H. and Neal, D. E. (1995). Long-term outcome related to epidermal growth factor receptor status in bladder cancer. J. Urol. 153, 919-925.
33. Miyamoto, S., Yagi, H., Yotsumoto, F., Kawarabayashi, T. and Mekada, E. (2006). Heparin-binding epidermal growth factor-like growth factor as a novel targeting molecule for cancer therapy. Cancer Sci. 97, 341-347.
34. Morotti, A., Mila, S., Accornero, P., Tagliabue, E. and Ponzetto, C. (2002). K252a inhibits the oncogenic properties of Met, the HGF receptor. Oncogene 21, 4885-4893.
35. Murillo, M. M., del Casillo, G., Sanchez, A., Fernandez, M. and Fabregat, I. (2005). Involvement of EGF receptor and c-Src in the survival signals induced by TGF-β1 in hepatocytes. Oncogene 24, 4580-4587.
36. Neal, D. E., Sharples, L., Smith, K., Fennelly, J., Hall, R. R. and Harris, A. L. (1990). The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 65, 1619-1625.
37. Neel, B. D., Aouacheria, A., Nouvion, A. L., Ronot, X. and Gillet, G. (2005). Distinct protease pathways control cell shape and apoptosis in v-src-transformed quail neuroretina cells. Exp. Cell Res. 311, 106-116.
38. Peschard, P. and Park, M. (2003). Escape from Cbl-mediated downregulation: a recurrent theme for oncogenic deregulation of receptor tyrosine kinases. Cancer Cell 3, 519-523.
39. Peschard, P., Fournier, T. M., Lamorte, L., Naujokas, M. A., Band, H., Langdon, W. Y. and Park, M. (2001). Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol. Cell 8, 995-1004.
40. Peschard, P., Ishiyama, N., Lin, T., Lipkowitz, S. and Park, M. (2004). A conserved DpYR motif in the juxtamembrane domain of the Met receptor family forms an atypical c-Cbl/Cbl-b tyrosine kinase binding domain binding site required for suppression of oncogenic activation. J. Biol. Chem. 279, 29565-29571.
41. Ponzetto, C., Bardelli, A., Zhen, Z., Maina, F., dalla Zonca, P., Giordano, S., Graziani, A., Panayotou, G. and Comoglio, P. M. (1994). A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 77, 261-271.
42. Popsueva, A., Poteryaev, D., Arighi, E., Meng, X., Angers-Loustau, A., Kaplan, D., Saarma, M. and Sariola, H. (2003). GDNF promotes tubulogenesis of GFRα1-expressing MDCK cells by Src-mediated phosphorylation of Met receptor tyrosine kinase. J. Cell Biol. 161, 119-129.
43. Prenzel, N., Zwick, E., Daub, H., Leserer, M., Abraham, R., Wallasch, C. and Ulbrich, A. (1999). EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 402, 884-888.
44. Qiao, H., Saulnier, R., Patryzkat A., Rahimi, N., Raptis, L., Rossiter, J., Tremblay, E. and Elliott, B. (2000). Cooperative effect of hepatocyte growth factor and fibronectin in anchorage-independent survival of mammary carcinoma cells: requirement for phosphatidylinositol 3-kinase activity. Cell Growth Differ. 11, 123-133.
45. Rahimi, N., Tremblay, E., McAdam, L., Park, M., Schwall, R. and Elliott, B. (1996). Identification of a hepatocyte growth factor autocrine loop in a murine mammary carcinoma. Cell Growth Differ. 7, 263-270.
46. Rahimi, N., Hung, W., Tremblay, E., Saulnier, R. and Elliott, B. (1998). c-Src kinase activity is required for hepatocyte growth factor-induced motility and anchorage-independent growth of mammary carcinoma cells. J. Biol. Chem. 273, 33714-33721.
47. Ruck, A. and Paulie, S. (1997). The epidermal growth factor receptor is involved in autocrine growth of human bladder carcinoma cell lines. Anticancer Res. 17, 1925-1931.
48. Ruck, A. and Paulie, S. (1998). EGF, TGF alpha, AR and HB-EGF are autocrine growth factors for human bladder carcinoma cell lines. Anticancer Res. 18, 1447-1452.
49. Ruck, A., Jakobson, E., Bjorkman, S. and Paulie, S. (1994). Adaptation of human bladder carcinoma cell lines to serum-free growth. Evidence for autocrine growth stimulation. Anticancer Res. 14, 55-60.
50. Sato, K., Sato, A, Aoto, M. and Fukami, Y. (1995). c-Src phosphorylates epidermal growth factor receptor on tyrosine 845. Biochem. Biophys. Res. Commun. 215, 1078-1087.
51. Sato, K., Kimoto, M., Kakumoto, M., Horiuchi, D, Iwasaki, T., Tokmakov, A. A. and Fukami, Y. (2000). Adaptor protein Shc undergoes tnanslocation and mediates upregulation of the tyrosine kinase c-Src in EGF-stimulated A431 cells. Genes Cells 5, 749-764.
52. Sato, K., Nagao, T., Kakumoto, M., Kimoto, M., Otsuki, T., Iwasaki, T., Tokmakov, A. A., Owada, K. and Fukami, Y. (2002). Adaptor protein Shc is an isoform-specific activator of the tyrosine kinase c-Src. J. Biol. Chem. 277, 29568-29576.
53. waf1 pathway in A431 cells. Genes Cells 8, 935-943.
54. Sato, K., Iwasaki, T., Hirahara, S., Nishihira, Y. and Fukami, Y. (2004). Molecular dissection of egg fertilization signaling with the aid of tyrosine kinase-specific inhibitor and activator strategies. Biochim. Biophys. Acta 1697, 103-121.
55. Saucier, C., Khoury, H., Lai, K. M., Peschard, P., Dankort, D., Naujokas, M. A., Holash, J., Yancopoulos, G. D., Muller, W. J., Pawson, T. et al. (2004). The Shc adaptor protein is critical for VEGF induction by Met/HGF and ErbB2 receptors and for early onset of tumor angiogenesis. Proc. Natl. Acad. Sci. USA 101, 2345-2350.
56. Schafer, B., Gschwind, A. and Ullrich, A. (2004). Multiple G-protein-coupled receptor signals converge on the epidermal growth factor receptor to promote migration and invasion. Oncogene 23, 991-999.
57. Sporn, M. B. and Roberts, A. B. (1985). Autocrine growth factors and cancer. Nature 313, 745-747.
58. Sridhar, S. C. and Miranti, C. K. (2005). Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integrin-dependent crosstalk with c-Met receptor and Src kinases. Oncogene 25, 2367-2378.
59. Stennicke, H. R. and Salvesen, G. S. (2000). Caspases - controlling intracellular signals by protease zymogen activation. Biochim. Biophys. Acta 1477, 299-306.
60. Summy, J. M. and Gallick, G. E. (2006). Treatment for advanced tumors: SRC reclaims center stage. Clin. Cancer Res. 12, 1398-1401.
61. Suzuki, M., Raab, G., Moses, M. A., Fernandez, C. A. and Klagsbrun, M. (1997). Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site. J. Biol. Chem. 272, 31730-31737.
62. Thomas, S. M. and Brugge, J. S. (1997). Cellular functions regulated by Src family kinases. Annu. Rev. Cell Dev. Biol. 13, 513-609.
63. Thogersen, V. B., Sorensen, B. S., Poulsen, S. S., Orntoft, T. F., Wolf, H. and Nexo, E. (2001). A subclass of HER1 ligands are prognostic markers for survival in bladder cancer patients. Cancer Res. 61, 6227-6233.
64. Wang, W., Marimuthu, A., Tsai, J., Kumar, A., Krupka, H. I., Zhang, C., Powell, B., Suzuki, Y., Nguyen, H., Tabrizizad, M. et al. (2006). Structural characterization of autoinhibited c-Met kinase produced by coexpression in bacteria with phosphatase. Proc. Natl. Acad. Sci. USA 103, 3563-3568.
65. Wojcik, E. J., Sharifpoor, S., Miller, N. A., Wright, T. G., Watering, R., Tremblay, E. A., Swan, K., Mueller, C. R. and Elliott, B. E. (2006). A novel activating function of c-Src and Stat3 on HGF transcription in mammary carcinoma cells. Oncogene 25, 2773-2784.
66. 2+ binding of hepatocyte growth factor (HGF) interaction with its receptor Met and blockade of HGF/Met function. J. Biol. Chem. 279, 32499-32506.
67. Xiao, G. H., Jeffers, M., Bellacosa, A., Mitsuuchi, Y., Vande Woude, G. F. and Testa, J. R. (2001). Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc. Natl. Acad. Sci. USA 98, 247-252.
68. Zhang, Q., Thomas, S. M., Xi, S., Smithgall, T. E., Siegfried, J. M., Kamens, J., Gooding, W. E. and Grandis, J. R. (2004). SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells. Cancer Res. 64, 6166-6173.